Skip to main content
Clinical Trials/CTRI/2016/04/006809
CTRI/2016/04/006809
Not yet recruiting
未知

A comparative, observational study to evaluate the effect of narrow band UV-B therapy in patients with progressive non-segmental vitiligo versus non-progressive non- segmental vitiligo.

All India Institute of Medical Sciences0 sites30 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: null- Vitiligo
Sponsor
All India Institute of Medical Sciences
Enrollment
30
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Patients of either sex, aged 15\-60 years with a clinical diagnosis of non\-segmental vitiligo with any of the following features â??
  • a. Involving \>5 % BSA
  • b. Involving 2\-5 % BSA, but multi\-focal, scattered lesions confined to non\-contiguous areas of the body
  • 2\. With no systemic and no topical treatment for 1 month.
  • 3\. These patients will be divided into two groups.
  • a. Progressive vitiligo \- \>5 new lesions in past 1 month or \>15 new lesions in past 3 months,
  • b. Non\-progressive vitiligo \- no new lesions in the past 6 months.

Exclusion Criteria

  • 1\) Segmental vitiligo
  • 2\) Vitiligo involving \> 50 % BSA
  • 3\) Pregnant and lactating females
  • 4\) History of photosensitivity / photo\-aggravated dermatomes like SLE, xeroderma pigmentosum, basal cell nevus syndrome, prior history of skin carcinoma, photosensitive disorders, contact photosensitive substances, photosensitizing medications with an action spectrum with the corresponding UVA or UVB wave\-lengths etc.
  • 5\) Inability to attend dermatology clinic for 3 sessions per week (or at least 2 sessions per week) for NB\-UVB phototherapy
  • 6\) Lip\-tip vitiligo or acrofacial variant only with tips of fingers and toes and lip involvement
  • 7\) Pure mucosal vitiligo
  • 8\) Patients with immuno\-compromised states, like HIV/AIDS etc.
  • 9\) Patients with malignancies (cutaneous and internal)

Outcomes

Primary Outcomes

Not specified

Similar Trials